Abstract Polycythemia vera (PV) is a myeloproliferative neoplasm associated with increased risk of thrombotic events (TE) and death. Therapeutic interventions, phlebotomy and cytoreductive medications, are targeted to maintain hematocrit levels < 45% to prevent adverse outcomes. This retrospective observational study examined medical and pharmacy claims of 28,306 PV patients initiating treatment for PV in a data period […]
BESREMi, Ropeginterferon FDA approved Treatment for PV
by David Wallace Patients are Asking – MPN Expert Dr. Ghaith Abu-Zeinah discusses Ropeginterferon (BESREMi), new Treatment for Polycythemia Vera Episode 3 of 3 Ropeginterferon / BESREMi was recently approved by the FDA to treat polycythemia vera. Should I switch from Pegasys to the new FDA approved interferon? How might BESREMi change the treatment paradigm […]
Clinical Trial Update on Emerging MPN Treatments
by David Wallace Find out the latest news on Ropeginterferon and PTG-300 for treating polycythemia vera, as well as the most promising new treatments for myelofibrosis. What’s the clinical significance of the Allele Burden (AB)? Are there common elements between COVID-19 and MPN…should you get the vaccine? Learn more as Dr. Srdan Verstovsek, Professor, Department of […]
